Prevalence of novel psychoactive substances in selected clinical urine specimens submitted for drug monitoring
- 1Quest Diagnostics Nichols Institute R&D Toxicology Chantilly Virginia USA
Abstract
Novel psychoactive substances (NPS) are compounds emerging as alternatives to more established drugs of abuse. They are constantly changing and being modified, which makes their detection difficult. The study objective was to determine the prevalence of NPS in selected clinical specimens. Deidentified urine specimen remnants were analyzed that had previously been submitted for testing from six different regions in the United States and representing three different clinical categories: specimens submitted for smaller legacy LC–MS/MS NPS panels (ie, NPS–targeted, negative test results), immunoassay‐positive but LC–MS/MS–negative traditional benzodiazepine and opiate specimens, and fentanyl/norfentanyl LC–MS/MS–positive specimens. A new, validated, large‐panel LC–MS/MS method analyzed for 88 NPS including designer fentanyl analogs, designer benzodiazepines, designer opioids, designer stimulants and hallucinogens, synthetic cannabinoids, and other additives (e.g., xylazine). In total, 3753 deidentified remnant specimens were analyzed between March and July 2023 with 13.3% of specimens testing positive for ≥1 NPS, with 30 different NPS detected; most of which were from the Eastern part of the United States. Xylazine was the most prevalent NPS and was detected in all regions and specimen categories, but the other analytes were not consistently observed across the six regions. In terms of specimen remnant categories, NPS positivity was 5.5% for the NPS–targeted specimens, 10.7% for opiate/benzodiazepine specimens, and 43.7% for fentanyl/norfentanyl specimens. Our data demonstrate variability in the NPS landscape and that testing for NPS in clinical urine specimens can help give clinicians a better awareness of drug misuse among their patients.
Related
- Self-medication of attention-deficit/hyperactivity disorder symptoms with psychoactive substances in adults: a scoping review of how symptom-relief motives are framed and operationalised across substances
- The hidden severity of new psychoactive substances: clinical evidence from emergency and intensive care admissions in Taiwan.
- Measuring the Awareness Level of the Residents of Wilayat Sinaw in the Sultanate of Oman Regarding the Dangers of Drugs, Psychoactive Substances, and Electronic Cigarettes
- Crawling into the Unknown: Unveiling Novel Psychoactive Substances (NPSs) in the Post Pandemic Era Utilizing the NPSfinder®
- Early Warning System for New Psychoactive Substances surveillance in the Community of Madrid, Spain
BibTeX
@article{neifeld2026prevalence,
title = {{Prevalence of novel psychoactive substances in selected clinical urine specimens submitted for drug monitoring}},
author = {Jillian R. Neifeld and Theresa M. Meli and Sarah H. Bartock},
journal = {Journal of Forensic Sciences},
year = {2026},
month = jul,
doi = {10.1111/1556-4029.70406},
url = {https://doi.org/10.1111/1556-4029.70406},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Prevalence of novel psychoactive substances in selected clinical urine specimens submitted for drug monitoring
AU - Jillian R. Neifeld
AU - Theresa M. Meli
AU - Sarah H. Bartock
PY - 2026
DA - 2026/07/06
JO - Journal of Forensic Sciences
DO - 10.1111/1556-4029.70406
UR - https://doi.org/10.1111/1556-4029.70406
AB - Novel psychoactive substances (NPS) are compounds emerging as alternatives to more established drugs of abuse. They are constantly changing and being modified, which makes their detection difficult. The study objective was to determine the prevalence of NPS in selected clinical specimens. Deidentified urine specimen remnants were analyzed that had previously been submitted for testing from six different regions in the United States and representing three different clinical categories: specimens submitted for smaller legacy LC–MS/MS NPS panels (ie, NPS–targeted, negative test results), immunoassay‐positive but LC–MS/MS–negative traditional benzodiazepine and opiate specimens, and fentanyl/norfentanyl LC–MS/MS–positive specimens. A new, validated, large‐panel LC–MS/MS method analyzed for 88 NPS including designer fentanyl analogs, designer benzodiazepines, designer opioids, designer stimulants and hallucinogens, synthetic cannabinoids, and other additives (e.g., xylazine). In total, 3753 deidentified remnant specimens were analyzed between March and July 2023 with 13.3% of specimens testing positive for ≥1 NPS, with 30 different NPS detected; most of which were from the Eastern part of the United States. Xylazine was the most prevalent NPS and was detected in all regions and specimen categories, but the other analytes were not consistently observed across the six regions. In terms of specimen remnant categories, NPS positivity was 5.5% for the NPS–targeted specimens, 10.7% for opiate/benzodiazepine specimens, and 43.7% for fentanyl/norfentanyl specimens. Our data demonstrate variability in the NPS landscape and that testing for NPS in clinical urine specimens can help give clinicians a better awareness of drug misuse among their patients.
SN - 0022-1198
SN - 1556-4029
ER -